393 related articles for article (PubMed ID: 35850753)
21. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
22. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
23. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway.
Peng Y; He X; Chen H; Duan H; Shao B; Yang F; Li H; Yang P; Zeng Y; Zheng J; Li Y; Hu J; Lin L; Teng L
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061180
[TBL] [Abstract][Full Text] [Related]
25. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR
Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
27. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
Wang S; Chen C; Li J; Xu X; Chen W; Li F
J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells.
Zhu S; Guo J; Yu L; Liu J; Chen J; Xin J; Zhang Y; Luo J; Duan C
Sci Rep; 2023 Dec; 13(1):21835. PubMed ID: 38071213
[TBL] [Abstract][Full Text] [Related]
29. Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs.
Bashiri H; Moazam-Jazi M; Karimzadeh MR; Jafarinejad-Farsangi S; Moslemizadeh A; Lotfian M; Karam ZM; Kheirandish R; Farazi MM
Immunotherapy; 2023 Oct; 15(14):1157-1169. PubMed ID: 37584216
[TBL] [Abstract][Full Text] [Related]
30. Interplay of m
Li F; Chen S; Yu J; Gao Z; Sun Z; Yi Y; Long T; Zhang C; Li Y; Pan Y; Qin C; Long W; Liu Q; Zhao W
Clin Transl Med; 2021 Sep; 11(9):e553. PubMed ID: 34586728
[TBL] [Abstract][Full Text] [Related]
31. RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Chen Y; Mu Y; Guan Q; Li C; Zhang Y; Xu Y; Zhou C; Guo Y; Ma Y; Zhao M; Ji G; Liu P; Sun D; Sun H; Wu N; Jin Y
Cell Death Dis; 2023 Nov; 14(11):757. PubMed ID: 37985768
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
33. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
34. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
35. Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities.
Kao TJ; Lin CL; Yang WB; Li HY; Hsu TI
Lipids Health Dis; 2023 Aug; 22(1):114. PubMed ID: 37537607
[TBL] [Abstract][Full Text] [Related]
36. Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
You F; Li C; Zhang S; Zhang Q; Hu Z; Wang Y; Zhang T; Meng Q; Yu R; Gao S
Biomed Pharmacother; 2023 Jun; 162():114555. PubMed ID: 36966667
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B
Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580
[No Abstract] [Full Text] [Related]
38. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
Vengoji R; Atri P; Macha MA; Seshacharyulu P; Perumal N; Mallya K; Liu Y; Smith LM; Rachagani S; Mahapatra S; Ponnusamy MP; Jain M; Batra SK; Shonka N
J Exp Clin Cancer Res; 2021 Oct; 40(1):335. PubMed ID: 34696786
[TBL] [Abstract][Full Text] [Related]
39. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
[TBL] [Abstract][Full Text] [Related]
40. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]